Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities (2011 - 2026)

Ani Pharmaceuticals (ANIP) has 13 years of Other Non-Current Liabilities data on file, last reported at $8.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 22.51% year-over-year to $8.6 million; the trailing twelve-month figure through Mar 2026 stood at $8.6 million (up 22.51% YoY), and the FY2025 full-year result was $12.2 million, up 110.41% from the prior year.
• Other Non-Current Liabilities eased to $8.6 million in Q1 2026, from $12.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $32.1 million in Q1 2022 to a low of $1.0 million in Q2 2022.
• A 5-year average of $8.4 million and a median of $6.7 million in 2025 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities sank 96.25% in 2023 and soared 828.45% in 2024, its largest moves.
• Tracing ANIP's Other Non-Current Liabilities over 5 years: stood at $1.4 million in 2022, then surged by 248.23% to $4.8 million in 2023, then climbed by 20.21% to $5.8 million in 2024, then jumped by 110.41% to $12.2 million in 2025, then fell by 29.3% to $8.6 million in 2026.
• Business Quant data shows ANIP's Other Non-Current Liabilities at $8.6 million in Q1 2026, $12.2 million in Q4 2025, and $8.0 million in Q3 2025.